中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
30期
36-38
,共3页
杨晴%马传根%张义轩%信文启%张挚%陈宗
楊晴%馬傳根%張義軒%信文啟%張摯%陳宗
양청%마전근%장의헌%신문계%장지%진종
地佐辛%舒芬太尼%术后镇痛
地佐辛%舒芬太尼%術後鎮痛
지좌신%서분태니%술후진통
Dezocine%Sufentanil%Postoperative analgesia
目的:观察地佐辛与舒芬太尼在乳腺癌术后静脉自控镇痛(PCIA)的临床效果,探索更安全有效的术后镇痛方法。方法:选取择期行乳腺癌根治手术的患者90例,ASAⅠ~Ⅱ级,均采用全身麻醉,术后行PCIA。按随机数字表法将患者分为A、B、C三组,每组各30例。A组仅采用地佐辛镇痛,B组仅采用舒芬太尼镇痛,C组采用地佐辛+舒芬太尼联合镇痛。观察记录三组患者术后4、8、16、24、36、48 h 的疼痛评分(VAS),舒适度评分(BCS)以及观察恶心呕吐、头晕、皮肤瘙痒、尿潴留、呼吸抑制等不良反应的发生率。结果:术后各时间点A组的VAS评分高于B组和C组,差异均有统计学意义(P<0.05);A、B、C三组各时间点的BCS评分比较差异无统计学意义(P>0.05);B、C组的头晕发生率小于A组;B组的恶心呕吐、尿潴留、皮肤瘙痒和呼吸抑制的发生率高于A组和C组,其中恶心呕吐的比较差异有统计学意义(P<0.05)。结论:地佐辛联合舒芬太尼用于乳腺癌术后PCIA,效果确切满意,不良反应发生率小,经济性价值高,值得临床应用。
目的:觀察地佐辛與舒芬太尼在乳腺癌術後靜脈自控鎮痛(PCIA)的臨床效果,探索更安全有效的術後鎮痛方法。方法:選取擇期行乳腺癌根治手術的患者90例,ASAⅠ~Ⅱ級,均採用全身痳醉,術後行PCIA。按隨機數字錶法將患者分為A、B、C三組,每組各30例。A組僅採用地佐辛鎮痛,B組僅採用舒芬太尼鎮痛,C組採用地佐辛+舒芬太尼聯閤鎮痛。觀察記錄三組患者術後4、8、16、24、36、48 h 的疼痛評分(VAS),舒適度評分(BCS)以及觀察噁心嘔吐、頭暈、皮膚瘙癢、尿潴留、呼吸抑製等不良反應的髮生率。結果:術後各時間點A組的VAS評分高于B組和C組,差異均有統計學意義(P<0.05);A、B、C三組各時間點的BCS評分比較差異無統計學意義(P>0.05);B、C組的頭暈髮生率小于A組;B組的噁心嘔吐、尿潴留、皮膚瘙癢和呼吸抑製的髮生率高于A組和C組,其中噁心嘔吐的比較差異有統計學意義(P<0.05)。結論:地佐辛聯閤舒芬太尼用于乳腺癌術後PCIA,效果確切滿意,不良反應髮生率小,經濟性價值高,值得臨床應用。
목적:관찰지좌신여서분태니재유선암술후정맥자공진통(PCIA)적림상효과,탐색경안전유효적술후진통방법。방법:선취택기행유선암근치수술적환자90례,ASAⅠ~Ⅱ급,균채용전신마취,술후행PCIA。안수궤수자표법장환자분위A、B、C삼조,매조각30례。A조부채용지좌신진통,B조부채용서분태니진통,C조채용지좌신+서분태니연합진통。관찰기록삼조환자술후4、8、16、24、36、48 h 적동통평분(VAS),서괄도평분(BCS)이급관찰악심구토、두훈、피부소양、뇨저류、호흡억제등불량반응적발생솔。결과:술후각시간점A조적VAS평분고우B조화C조,차이균유통계학의의(P<0.05);A、B、C삼조각시간점적BCS평분비교차이무통계학의의(P>0.05);B、C조적두훈발생솔소우A조;B조적악심구토、뇨저류、피부소양화호흡억제적발생솔고우A조화C조,기중악심구토적비교차이유통계학의의(P<0.05)。결론:지좌신연합서분태니용우유선암술후PCIA,효과학절만의,불량반응발생솔소,경제성개치고,치득림상응용。
Objective:To investigate the effect of patient-controlled intravenous analgesia(PCIA)of Dezocine and Sufentanil in the patients with breast cancer after their surgical therapy,and to find out the safer and more effective postoperative analgesia. Method:90 breast cancer patients with radical surgery were selected,ASAⅠ-Ⅱlevel,were performed under the general anesthesia,followed by PCIA. Patients were randomly divided into the group A,B,C, 30 cases for each group. The group A only administered Dezocine,the group B only administered Sufentanil,the group C administered both Dezocine and Sufentanil. Pain score(VAS),comfort score(BCS)and the incidence of adverse reactions,which included nausea and vomiting,dizziness,skin itching,urinary retention,respiratory depression,were observed and assessed for postoperative 4,8,16,24,36 h and 48 h.Result:The VAS scores of the group A was higher than those of the group B and C at each time point for postoperation,and the differences were statistically significant (P<0.05);the differences of BCS scores of three groups at all time points had no statistical significance(P>0.05);the incidence of dizziness of both B and C group was less than the group A. The incidences of nausea and vomiting,urinary retention,itchy skin,and respiratory depression of the group B were higher than those of the group A and C,and the difference of nausea and vomiting had statistical significance(P<0.05).Conclusion:The combined application of Dezocine and Sufentanil for PCIA of postoperative breast cancer is worthy of clinically popularizing,because of the exact effect of analgesia,fewer incidence of adverse reactions and high economic value.